ReviewAbdominal radiology (New York)2026
Seeing the invisible: practical strategies to maximize the clinical impact of photon-counting CT in abdominal imaging.
Review in Abdominal radiology (New York), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Understanding Photon-Counting CT: Physics, Detector Technology, and Image Reconstructions.Sensors (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Photon-counting detector computed tomography (PCD-CT) represents a major technological advance, transforming abdominal imaging from morphology-based assessment to a platform that integrates spectral and quantitative information. Unlike conventional energy-integrating detector CT, PCD-CT directly converts X-ray photons into electrical signals, allowing inherent spectral imaging, improved spatial resolution, and enhanced dose efficiency. These characteristics enable flexible retrospective reconstruction, including virtual monoenergetic imaging and material decomposition, which can be tailored to specific clinical tasks and applications. These capabilities translate into meaningful clinical benefits in abdominal radiology. Low-keV imaging improves lesion conspicuity, facilitating the detection of subtle findings including early-stage pancreatic cancer, small metastases, and inflammatory changes. Further, spectral imaging improves tissue characterization, enabling differentiation between true and pseudoenhancement and supporting more accurate staging in oncologic imaging. Moreover, amplifying iodine contrast may enable substantial contrast dose reduction while maintaining diagnostic quality, potentially benefiting selected patients who require contrast optimization. PCD-CT may support the concept of "one-stop imaging" by providing both systemic and local diagnostic information within a single examination, potentially reducing the need for additional imaging in selected clinical scenarios. Quantitative imaging approaches, including iodine density mapping and extracellular volume assessment, provide functional information that may serve as imaging biomarkers for disease activity and treatment response. Emerging applications, including virtual noncalcium imaging, expand the role of CT into domains traditionally reserved for magnetic resonance imaging. Challenges including increased data volume, technical limitations, cost-effectiveness, and the need for optimized reconstruction strategies, remain despite these advantages. PCD-CT is poised to play a key role in abdominal radiology, shifting CT from simply "seeing more" to "measuring more" and "understanding more" as multi-energy imaging and quantitative techniques continue to evolve.
Indexed as
Identifiers
42390778What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.